Y-Biologics (XKRX:338840) Debt-to-Equity : 0.12 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Y-Biologics Debt-to-Equity?

Y-Biologics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩2,192 Mil. Y-Biologics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩700 Mil. Y-Biologics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ₩23,408 Mil. Y-Biologics's debt to equity for the quarter that ended in Dec. 2023 was 0.12.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Y-Biologics's Debt-to-Equity or its related term are showing as below:

XKRX:338840' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.12 Med: 0.28 Max: 0.4
Current: 0.12

During the past 6 years, the highest Debt-to-Equity Ratio of Y-Biologics was 0.40. The lowest was 0.12. And the median was 0.28.

XKRX:338840's Debt-to-Equity is ranked better than
55.59% of 1074 companies
in the Biotechnology industry
Industry Median: 0.15 vs XKRX:338840: 0.12

Y-Biologics Debt-to-Equity Historical Data

The historical data trend for Y-Biologics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Y-Biologics Debt-to-Equity Chart

Y-Biologics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

0.18

0.76

0.18

0.21

0.40

Y-Biologics Quarterly Data
	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial			0.40	0.23	0.28	0.37	0.12

Competitive Comparison of Y-Biologics's Debt-to-Equity

For the Biotechnology subindustry, Y-Biologics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Y-Biologics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Y-Biologics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Y-Biologics's Debt-to-Equity falls into.

Y-Biologics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Y-Biologics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4751.575	+	188.099)	/	12293.167
	=	0.40

Y-Biologics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2192.47	+	700.009)	/	23408.46
	=	0.12

Y-Biologics (XKRX:338840) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Y-Biologics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Y-Biologics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Y-Biologics (XKRX:338840) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-Biologics Inc (XKRX:338840) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 715, 17, Tech-ro 4-ro, Yuseong-gu, Daejeon, KOR

Website

https://www.ybiologics.com

Y-Biologics Inc is a company has a variety of development candidate antibodies based on Korea's highest-level antibody discovery platform technology and then independently develops antibody treatments or jointly develops cutting-edge biopharmaceuticals by fusing them with our partner's platform technology. Its main business model is based on a globally competitive antibody discovery platform and consists of development of new bio drug candidates and early technology transfer, and contract research services that generate stable cash flow.

Y-Biologics (XKRX:338840) Headlines

No Headlines